Regenxbio Inc (NASDAQ:RGNX) CFO Vittal Vasista sold 5,000 shares of the firm’s stock in a transaction that occurred on Tuesday, January 16th. The stock was sold at an average price of $30.16, for a total value of $150,800.00. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.

Vittal Vasista also recently made the following trade(s):

  • On Tuesday, December 19th, Vittal Vasista sold 5,000 shares of Regenxbio stock. The stock was sold at an average price of $30.00, for a total value of $150,000.00.

Shares of Regenxbio Inc (RGNX) traded down $0.33 during mid-day trading on Thursday, hitting $27.55. The stock had a trading volume of 353,913 shares, compared to its average volume of 688,150. The company has a market cap of $868.17 and a price-to-earnings ratio of -10.17. Regenxbio Inc has a 12-month low of $16.30 and a 12-month high of $36.45.

Regenxbio (NASDAQ:RGNX) last issued its quarterly earnings data on Wednesday, November 8th. The biotechnology company reported ($0.67) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.71) by $0.04. The firm had revenue of $1.34 million for the quarter. Regenxbio had a negative return on equity of 39.33% and a negative net margin of 764.06%. equities analysts anticipate that Regenxbio Inc will post -2.71 earnings per share for the current fiscal year.

A number of equities research analysts have recently weighed in on the company. BidaskClub lowered Regenxbio from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, January 9th. Raymond James Financial reiterated a “buy” rating on shares of Regenxbio in a research report on Friday, January 5th. Chardan Capital reiterated a “buy” rating on shares of Regenxbio in a research report on Monday, December 11th. TheStreet lowered Regenxbio from a “c” rating to a “d+” rating in a research report on Tuesday, November 28th. Finally, Barclays assumed coverage on Regenxbio in a research report on Wednesday, November 22nd. They issued an “overweight” rating and a $38.00 price objective on the stock. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $42.43.

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Legal & General Group Plc lifted its stake in shares of Regenxbio by 41.4% in the 2nd quarter. Legal & General Group Plc now owns 6,870 shares of the biotechnology company’s stock valued at $137,000 after purchasing an additional 2,011 shares during the period. Ardsley Advisory Partners purchased a new position in shares of Regenxbio in the 2nd quarter valued at approximately $197,000. Voya Investment Management LLC purchased a new position in shares of Regenxbio in the 2nd quarter valued at approximately $249,000. Asymmetry Capital Management L.P. lifted its stake in shares of Regenxbio by 12.2% in the 2nd quarter. Asymmetry Capital Management L.P. now owns 13,906 shares of the biotechnology company’s stock valued at $275,000 after purchasing an additional 1,508 shares during the period. Finally, Wells Fargo & Company MN lifted its stake in shares of Regenxbio by 1.1% in the 2nd quarter. Wells Fargo & Company MN now owns 16,209 shares of the biotechnology company’s stock valued at $320,000 after purchasing an additional 175 shares during the period. Institutional investors own 68.73% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This piece of content was originally posted by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are viewing this piece of content on another domain, it was stolen and reposted in violation of U.S. & international copyright & trademark laws. The correct version of this piece of content can be accessed at https://theolympiareport.com/2018/01/18/regenxbio-inc-rgnx-cfo-vittal-vasista-sells-5000-shares.html.

About Regenxbio

REGENXBIO Inc is a clinical-stage biotechnology company. The Company’s gene therapy product candidates are designed to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. The Company develops products candidates across the therapeutic areas of metabolic, neurodegenerative and retinal diseases.

Insider Buying and Selling by Quarter for Regenxbio (NASDAQ:RGNX)

Receive News & Ratings for Regenxbio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regenxbio and related companies with MarketBeat.com's FREE daily email newsletter.